MannKind has patented a drug delivery system using diketopiperazine carboxylate salts and microparticles, including bioactive agents. The method involves administering dry powder compositions containing a PDE5 inhibitor and a pharmaceutically acceptable salt of a heterocyclic compound to the pulmonary system through inhalation. GlobalData’s report on MannKind gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights MannKind Corp - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on MannKind, Smart inhalers was a key innovation area identified from patents. MannKind's grant share as of February 2024 was 54%. Grant share is based on the ratio of number of grants to total number of patents.

Dry powder composition for pulmonary delivery of pde5 inhibitor

Source: United States Patent and Trademark Office (USPTO). Credit: MannKind Corp

A recently granted patent (Publication Number: US11872265B2) discloses a method for delivering particles to the pulmonary system through the administration of a dry powder composition by inhalation. The composition includes a phosphodiesterase type 5 (PDE5) inhibitor and a pharmaceutically acceptable salt of a heterocyclic compound. The PDE5 inhibitor can be selected from sildenafil citrate, vardenafil hydrochloride, or tadalafil, with sodium being the preferred cation in the composition. The dry powder is prepared by removing a solvent through methods like spray drying, evaporation, or lyophilization, and can be micronized to form microparticles suitable for pulmonary delivery.

Furthermore, the patent claims the method's effectiveness in the absorption of PDE5 inhibitors into the circulatory system, with the potential for immediate and sustained absorption when the dry powder composition includes cations formed from sodium and calcium. The formulation of the dry powder into a solid dosage form is also mentioned in the claims, along with the importance of the microparticles having a diameter less than 5 µm and a rugosity of less than 2 for optimal pulmonary delivery. The patent highlights the innovative approach to delivering PDE5 inhibitors through dry powder inhalation, potentially offering a more efficient and targeted treatment method for patients in need.

To know more about GlobalData’s detailed insights on MannKind, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies